


PRODUCT INFORMATION



AZD 1208

Item No. 20235

CAS Registry No.: 1204144-28-4
Formal Name: (5Z)-[[2-[(3R)-3-amino-1-piperidinyl][1,1'-biphenyl]-3-yl]methylene]-2,4-thiazolidinedione
MF: C₂₁H₂₁N₃O₂S
FW: 379.5
Purity: ≥98%
UV/Vis.: λ_{max}: 230, 327 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZD 1208 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 1208 in the solvent of choice, which should be purged with an inert gas. AZD 1208 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of AZD 1208 in these solvents is approximately 1 and 0.1 mg/ml, respectively.

AZD 1208 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AZD 1208 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. AZD 1208 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

AZD 1208 is a potent, selective, and orally available inhibitor of all three forms of the proto-oncogene Pim kinase (IC₅₀s = 0.4, 5.0, and 1.9 nM for Pim-1, Pim-2, and Pim-3, respectively).¹ It causes cell cycle arrest and apoptosis in MOLM-16 megakaryoblastic leukemia cells and inhibits the growth of MOLM-16 xenograft tumors in mice.¹ It has efficacy against acute myeloid leukemia and glioblastoma cells when combined with mTOR and p110α inhibitors, respectively.^{2,3}

References

- Keeton, E. K., McEachern, K., Dillman, K. S., *et al.* AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. *Blood* **123**(6), 905-913 (2014).
- Harada, M., Benito, J., Yamamoto, S., *et al.* The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. *Oncotarget* **6**(35), 37930-37947 (2015).
- Iqbal, A., Eckerdt, F., Bell, J., *et al.* Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. *Oncotarget* **7**(22), 33192-33201 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM